Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
12.60
+0.30 (2.44%)
Jul 30, 2025, 4:00 PM - Market closed
Company Description
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients.
Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors.
The company is headquartered in Waltham, Massachusetts.
Crescent Biopharma, Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Joshua Brumm |
Contact Details
Address: 300 5th Avenue Waltham, Massachusetts 02451 United States | |
| Phone | 617-430-5595 |
| Website | crescentbiopharma.com |
Stock Details
| Ticker Symbol | CBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001124105 |
| CUSIP Number | 14888D208 |
| ISIN Number | US4037831033 |
Key Executives
| Name | Position |
|---|---|
| Joshua T. Brumm | Chief Executive Officer and Director |
| Dr. Jonathan McNeill M.D. | President and Chief Operating Officer |
| Richard William Scalzo M.B.A. | Chief Financial Officer |
| Ryan Lynch | Senior Vice President of Finance, Treasurer and Chief Accounting Officer |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer |
| Barbara H. Bispham J.D. | General Counsel and Corporate Secretary |
| Amy Reilly | Chief Communications Officer |
| Chris Doughty | Chief Business Officer |
| Dr. Wenjie Cheng Ph.D. | Senior Vice President of Technical Operations |
| Dr. Ellie Im M.D. | Chief Medical Officer |